Randy Milby - 13 Jan 2025 Form 4 Insider Report for Tharimmune, Inc. (THAR)

Reporting relationship: CEO, Director
Issuer ticker: THAR
Reported as of: 13 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jan 2025, 16:47:22 UTC
Prior SEC filing: 20 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Randy Milby

Key filing fact

Randy Milby filed Form 4 for Tharimmune, Inc. (THAR) on 14 Jan 2025.

Key facts

This page summarizes Randy Milby's Form 4 filing for Tharimmune, Inc. (THAR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jan 2025, 16:47.

Change

Previous filing in this sequence was filed on 20 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

THAR transaction Derivative

Options (right to buy)

Award

Transaction value: $0
Shares: +80,958
Change %: +140%
Price: $0.000000
Shares after: 138,665
Date: 13 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,958
Exercise price: $1.93
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On January 13, 2025, the Reporting Person was granted options ("Options") to purchase up to 80,958 shares of the Registrant's common stock pursuant to the Registrant's 2023 Omnibus Equity Incentive Plan. The Options vested in full upon grant.